Navigation Links
Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Date:11/30/2007

OXFORD, England, Nov. 30 /PRNewswire/ -- Chroma Therapeutics Limited announced today that it will report efficacy data from a Phase I clinical trial of its oral, once-daily experimental cancer therapy CHR-2797 at the forthcoming American Society of Hematology (ASH) meeting. CHR-2797 is the only oral aminopeptidase inhibitor currently in clinical development. The company will also be presenting the results of various preclinical studies. Details of the presentations are as follows:

Abstract # 443: oral presentation

Title: A Phase I Study of CHR-2797, an Orally Active Aminopeptidase

Inhibitor in Elderly and/or Treatment Refractory Patients with Acute

Myeloid Leukemia

Location and timing: Acute Myeloid Leukemias: Therapy, excluding

Transplantation-Novel Therapies, Rooms A411-A412: Monday December 10,

2007, 13:30-15:00 Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

Abstract # 1608, Poster # 762

Title: Cellular Aminopeptidase Inhibition as a Target for the Therapy of

AML by the Novel Agent CHR-2797

Location and timing: Poster Session I, Hall B4: Saturday, December 8,

2007, 17:30-19:30 Eastern Standard Time

Presenter: Dr Chris Jenkins (University Hospital, Cardiff, UK)

Abstract # 2505, Poster # 695

Title: Aminopeptidase Inhibition as a Targeted Treatment Strategy in

Myeloma

Location and timing: Poster Session II, Hall B4: Sunday, December 9,

2007, 18:00-20:00, Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

The ASH posters will be available at the company's website, http://www.chromatherapeutics.com following the above presentations.

Enquiries

Chroma Therapeutics Limited

Ian Nicholson Chief Executive Officer +44 (0)1235 829120

Richard Bungay Chief Financial Officer

Brunswick

Jon Coles +44 (0)20 7404 5959

Justine McIlroy

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at http://www.chromatherapeutics.com.


'/>"/>
SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chromatin remodeling complex connected to DNA damage control
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 20, 2017 , ... “Psalms of Humidity”: is a fascinating depiction of daily ... readers one step closer to God. “Psalms of Humidity” is the creation of published ... been made within his life are the very same things that have shaped him ...
(Date:9/20/2017)... ... 2017 , ... “The Financial Favor of God; Second Edition”: a personal and ... is the creation of published author, Brooks Rathell. , “We typically hear about the ... about the financial favor of God. Not only does it exist, but it is ...
(Date:9/20/2017)... ... , ... “Monique”: is the story of Monique, whose mother’s deteriorating physical ... author, Colleen Crispi, has owned four beauty salons and written a book regarding the ... and cooking. , “The doctor’s office was only three blocks away, and she ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected ... own Ross A. Clevens, MD, FACS . The founder and medical director of ... Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. He has ...
(Date:9/19/2017)... Alabama (PRWEB) , ... September 19, 2017 , ... ... customer success story on St. Vincent’s Infusion Services called, “PAPA Healthcare helps fill ... St. Vincent’s Infusion Services enhanced service delivery and operations by leveraging PAPA Healthcare’s ...
Breaking Medicine News(10 mins):
(Date:8/29/2017)... Aug. 29, 2017 In a move that ... regulatory compliance for veterinary practices of all sizes, Cubex ... partnership that makes TITAN,s expertise in physical security, drug ... Cubex,s clients nationally. ... handling controlled substances is at risk today," said TITAN ...
(Date:8/28/2017)... 28, 2017   Aesculight ®, a division of LightScalpel ®, ... lasers. Built on over 20 years of American veterinary laser surgery innovation, ... Exclusive VetScalpel®Features and Enhancements ... is excising a tumor with his new VetScalpel laser. Dr. Duclos practices ... ...
(Date:8/25/2017)... 25, 2017   West Pharmaceutical Services, Inc. (NYSE: ... administration, announced that management will be presenting a West business ... Management will present at the Baird 2017 ... New York, N.Y. , at 3:10 p.m. ... Conference, at the Westin Boston Waterfront in Boston, ...
Breaking Medicine Technology: